As Candel Therapeutics gears up for a planned U.S.
Candel Therapeutics is preparing a U.S. approval push for its prostate cancer drug later this year, backed by a $100 million financing deal from RTW Investments to fund the launch.
Why it mattersAn expected FDA approval decision later this year, supported by $100 million, enables nationwide commercial launch.